Form 4: NewAmsterdam Pharma Co N.V.: Chief Business Officer Reports Acquisition of 14,000 Ordinary Shares

Juliette Berangere Audet, Chief Business Officer of NewAmsterdam Pharma Co N.V., reports the acquisition of 14,000 ordinary shares through restricted stock units.

Summary

• On January 7, 2025, Juliette Berangere Audet, the Chief Business Officer of NewAmsterdam Pharma Co N.V., acquired 14,000 ordinary shares through the vesting of restricted stock units (RSUs).
• Each RSU represents a contingent right to receive one ordinary share.
• 1/3 of the RSUs will vest on each of the first, second, and third anniversaries of the vesting start date, contingent upon the Reporting Person's continued service.
• The RSUs were granted on January 7, 2025, for no consideration.
• Following the transaction, Audet beneficially owns 15,104 ordinary shares.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard regulatory filing detailing an insider transaction. The acquisition of shares by an officer is generally viewed as a positive sign, but the document itself is purely informational.

Positives

• The acquisition of shares by a key officer could be seen as a positive signal, indicating confidence in the company's future prospects.

Future Outlook

The vesting schedule of the RSUs extends over three years, contingent on continued service, suggesting a long-term commitment from the Chief Business Officer.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the ownership changes of key personnel.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder sentiment, as it indicates confidence from a key officer.

Key Dates